Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones

BACKGROUND: The ongoing global malaria eradication campaign requires development of potent, safe, and cost-effective drugs lacking cross-resistance with existing chemotherapies. One critical step in drug development is selecting a suitable clinical candidate from late leads. The process used to sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yizhe, Zhu, Fangyi, Hammill, Jared, Holbrook, Gloria, Yang, Lei, Freeman, Burgess, White, Karen L., Shackleford, David M., O’Loughlin, Kathleen G., Charman, Susan A., Mirsalis, Jon C., Guy, R. Kiplin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893776/
https://www.ncbi.nlm.nih.gov/pubmed/33608015
http://dx.doi.org/10.1186/s12936-021-03617-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893776/
https://www.ncbi.nlm.nih.gov/pubmed/33608015
http://dx.doi.org/10.1186/s12936-021-03617-1

Ejemplares similares